The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas-Reference-Cited by-同舟云学术

The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas

Published:2000-07 Issue:1 Volume:53 Page:53-60
ISSN:0300-0664
Container-title:Clinical Endocrinology
language:en
Short-container-title:Clinical Endocrinology

Author:

Di Sarno Antonella,Landi Maria Luisa,Marzullo Paolo,Di Somma Carolina,Pivonello Rosario,Cerbone Gaetana,Lombardi Gaetano,Colao Annamaria

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism,Endocrinology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2265.2000.01016.x/fullpdf

Reference27 articles.

1. Dopamine agonists and pituitary tumor shrinkage;Bevan;Endocrine Reviews,1992

2. Treatment of prolactin-secreting macroadenoma with once-a-week dopamine agonist cabergoline;Biller;Journal of Clinical Endocrinology and Metabolism,1996

3. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine;Brue;Journal of Clinical Endocrinology and Metabolism,1992

4. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma;Cannavò;Journal of Endocrinological Investigation,1999

5. Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients;Ciccarelli;Journal of Clinical Endocrinology and Metabolism,1989

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis of cyclic sulfamides via one pot alkylation/aza-Michael cascade reaction;Tetrahedron Letters;2024-09

2. Recovery from hypogonadism in men with prolactinoma treated with dopamine agonists;Pituitary;2024-08-19

3. Synthesis of Cyclic Sulfamides Via One Pot Alkylation/Aza-Michael Cascade Reaction;2024

4. How to manage intolerance to dopamine agonist in patients with prolactinoma;Pituitary;2023-04

5. Approach to the Patient With Prolactinoma;The Journal of Clinical Endocrinology & Metabolism;2023-03-28